Please note that this symposium will take place as an in-person event in Boston and will not live-stream content for virtual participation. The symposium content will be recorded and made available as an on-demand program after the symposium. Please visit the Registration page for details.

CME credit is available for in-person attendance for the designated sessions. On-demand presentations are not eligible for CME.

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.

*-Short talk from proffered abstract

Monday, March 4

• Welcome and Opening Keynote
• Plenary Session 1: Genetic Predisposition

Tuesday, March 5

• Plenary Session 2: Somatic Genomic Lesions
• Plenary Session 3: Precursor Conditions
• Plenary Session 4: Tumor Microenvironment
• Plenary Session 5: Epigenetic Pathways

Wednesday, March 6

• Keynote Lecture 2
• Plenary Session 6: Molecular Diagnosis and Prognosis
• Plenary Session 7: Immune Therapy and Escape
• Plenary Session 8: Precision Medicine
• Closing Comments and Departure

Registration 
ESSEX BALLROOM FOYER
3-8 p.m. 

Welcome and Opening Keynote
ESSEX BALLROOM sOUTH
5-6 p.m.

• Welcome and Introduction of Keynote Speaker (Not CME Eligible)
  Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, Massachusetts
  Riccardo Dalla-Favera, Columbia University, New York, New York
• Keynote Lecture
  A new human hematopoietic stem cell that retains memory of prior inflammatory stresses links inflammation, aging, CH and pre-leukemia initiation
  John E. Dick, UHN Princess Margaret Cancer Centre, Toronto, ON, Canada 

Plenary Session 1: Genetic Predisposition
ESSEX BALLROOM sOUTH
6-8:05 p.m.

Session Chair: Jennifer R. Brown, Dana-Farber Cancer Institute, Boston, Massachusetts

• The new genomics of T-lineage acute lymphoblastic leukemia
  Charles G. Mullighan, St. Jude Children’s Research Hospital, Memphis, Tennessee
• Germline predisposition to chronic lymphocytic leukemia
  Jennifer R. Brown
• Impact of germline and somatic ATM variants in Chronic Lymphocytic Leukemia (CLL): Clinical implications and response to PARP inhibition*
  Kiyomi Mashima, Dana-Farber Cancer Institute, Boston, Massachusetts
• Genetic determinants of racial disparities in multiple myeloma
  Francesco Maura, University of Miami, Miami, Florida

Opening Reception 
ESSEX BALLROOM cENTER
8:05-10 p.m.

Continental Breakfast: Meet the Blood Cancer Discovery Editors 
ESSEX BALLROOM nORTH
7-8 a.m.

Plenary Session 2: Somatic Genomic Lesions
ESSEX BALLROOM sOUTH
8-9:50 a.m. 

Session Chair: Laura Pasqualucci, Columbia University, New York, New York

• Invariant somatic mutations identify distinct subgroups of multiple myeloma
  P. Leif Bergsagel, Mayo Clinic, Phoenix, Arizona
• Genetics-driven dysregulation of super enhancer networks in diffuse large B-cell lymphoma
  Laura Pasqualucci
• Somatic mutations in peripheral T-cell lymphoma: Lineage specification and microenvironment remodeling
  Teresa Palomero, Institute for Cancer Genetics, Columbia University Irving Medical Center, New York, New York

Break 
ESSEX BALLROOM FOYER
9:50-10:10 a.m.

Plenary Session 3: Precursor Conditions
ESSEX BALLROOM sOUTH
10:10 a.m.-12 p.m.

Session Chair: Ross L. Levine, Memorial Sloan-Kettering Cancer Center, New York, New York

• Deciphering and targeting clonal hematopoiesis
  Ross L. Levine
• The promise of early detection and interception of multiple myeloma
  Irene M. Ghobrial, Dana-Farber Cancer Institute, Boston, Massachusetts
• Genetic & epigenetic evolution of follicular lymphoma precursors & their transformation
  Ash A. Alizadeh, Stanford University, Stanford, California

Lunch on Own / Free Time
12-2 p.m.

Plenary Session 4: Tumor Microenvironment
ESSEX BALLROOM sOUTH
2-3:50 p.m.

Session Chair: Madhav V. Dhodapkar, Emory University, Atlanta, Georgia

• Follicular lymphoma tumor microenvironment: T cell-stroma interactions at the front 
  Karin Tarte, University of Rennes, Rennes, France
• Regulation of immune microenvironment in plasma cell tumors
  Madhav V. Dhodapkar
• Regulation of T cell interactions in myeloid leukemia
  Iannis Aifantis, New York University, New York, New York

Break 
ESSEX BALLROOM FOYER
3:50-4:10 p.m.

Plenary Session 5: Epigenetic Pathways
ESSEX BALLROOM sOUTH
4:10-6:30pm

Session Chair: Ari M. Melnick, Weill Cornell Cancer Center, New York, New York

• Epigenetic mechanisms and therapy of B cell lymphomas
  Ari M. Melnick
• ARID1A mutations shape memory B-cell dynamics and confer sensitivity to SWI/SNF remodeling complex inhibition in lymphoma*
  Darko Barisic, Weill Cornell Medicine, New York, New York
• Mitochondrial and metabolic pathways in AML: Biological insights and new therapeutic targets
  Aaron D. Schimmer, University of Toronto, Toronto, Ontario, Canada
• Decoding cancer dependency and molecular pathways of long noncoding RNAs with a novel CRISPR-Cas13d platform*
  Eugenio Morelli, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy
• Separating and uniting genetic and cellular hierarchies in myeloid leukemia
  Eirini Papapetrou, Icahn School of Medicine at Mount Sinai, New York, New York

Poster Session and Reception
ESSEX BALLROOM NORTH 
6:45-8:45 p.m.

Dinner on Own / Free Time 
8:45 p.m.

Continental Breakfast 
ESSEX BALLROOM north
7-8 a.m.

Keynote Lecture 
ESSEX BALLROOM sOUTH
8-8:50 a.m.

Session Chair: Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, Massachusetts

• Novel paradigms for drug development in hematologic malignancies
  Nicole J. Gormley, U.S. Food and Drug Administration Center for Drug Evaluation and Research, Silver Spring, Maryland

Break 
ESSEX BALLROOM foyer
8:50-9 a.m. 

Plenary Session 6: Molecular Diagnosis and Prognosis 
ESSEX BALLROOM sOUTH
9-11:05 a.m.

Session Chair: Anthony Letai, Dana-Farber Cancer Institute, Boston, Massachusetts

• Functional precision medicine in blood cancers
  Anthony Letai
• Leveraging probabilistic causal disease models to understand molecular pathways and target resistance mechanisms in Multiple Myeloma with the CREBBP and EP300 bromodomain inhibitor, pocenbrodib*
  Allison Roder, Pathos AI, Salt Lake City, Utah
• Kinetics and biology of CTCs and MRD: Two dynamic high-risk clones in multiple myeloma
  Bruno Paiva, University of Navarra, Pamploma, Spain
• Exploring classic Hodgkin Lymphoma genetics through liquid biopsy
  Davide Rossi, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

Break
ESSEX BALLROOM foyer
11:05-11:20 a.m.

Plenary Session 7: Immune Therapy and Escape
ESSEX BALLROOM sOUTH
11:20 a.m.-1:25 p.m.

Session Chair: Eric L. Smith, Dana-Farber Cancer Institute, Boston, Massachusetts

• Molecular determinants of response and resistance to lymphoma immunotherapy
  Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, Massachusetts
• RHOA inactivation subverts IFN-γ response and promotes antigen escape in CAR-T resistant diffuse large B-cell lymphoma*
  Austin Newsam, University of Miami Miller School of Medicine, Miami, Florida
• Novel CAR targets for hematologic malignancies
  Marcela V. Maus, Massachusetts General Hospital, Boston, Massachusetts
• GABARAP deficiency drives resistance to immunogenic chemotherapy in multiple myeloma*
  Marcello Turi, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy
• Addressing mechanisms of resistance to T cell redirection immunotherapies for multiple myeloma
  Eric L. Smith

Lunch (provided) 
ESSEX BALLROOM foyer
1:25-1:45 p.m. 

Plenary Session 8: Precision Medicine 
ESSEX BALLROOM sOUTH
1:45-3:50 p.m.

Session Chair: Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, Massachusetts

• Curing aggressive lymphomas with aggressive combinations of drugs targeting oncogenic mechanisms
  Louis M. Staudt, National Cancer Institute, Bethesda, Maryland
• Title to be announced*
  Yoke Seng Lee, Harvard Medical School/Brigham and Women’s Hospital, Boston, Massachusetts
• Is there a role for precision medicine in multiple myeloma?
  Faith E. Davies, NYU Langone Health, Perlmutter Cancer Center, New York, New York
• Altered RNA export sensitizes to nuclear export inhibition in SF3B1 mutant MDS*
  Sana Chaudhry, University of Miami Miller School of Medicine, Miami, Florida
• Targeted protein degradation for the treatment of hematologic malignancies
  Benjamin L. Ebert, Dana-Farber Cancer Institute, Boston, Massachusetts

Closing Comments and Departure 
ESSEX BALLROOM sOUTH
3:50 p.m.

• Riccardo Dalla-Favera, Columbia University, New York, New York